(secondQuint)Treatment for Nicotine Addiction in Women.

 The proposed trail will be use a double-blind, placebo-controlled design to conduct the first randomized controlled trial of the COMT inhibitor, tolcapone, in nicotine dependent women.

 This study will determine if tolcapone is superior to placebo by attenuation the severity of nicotine withdrawal and smoking urges during short-term abstinence.

 Withdrawal severity will be assessed by a self-report scale and cognitive assessment, including a sustained-attention task.

 Smoking urges will be assessed by a self-report scale.

.

 Treatment for Nicotine Addiction in Women@highlight

The purpose of this study is to use a medication tolcapone and or placebo to test if the symptoms of nicotine withdrawal lessens , and or changes in smoking urges, and mental reasoning in female smokers over a 72 hour period.

